Intas Pharmaceuticals informed that the company has launched Intacept – a biosimilar to Amgen’s Enbrel (entanercept) in the strengths of 25mg in 0.5 ml and 50mg in 1.0 ml preservative free solution in pre-filled syringes.
Etanercept is indicated for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Plaque Psoriasis all debilitating autoimmune diseases, the company stated.
Commenting on the launch, Binish Chudgar, vice-chairman, Intas said, “Etanercept is a fusion protein that is difficult to develop. Intacept is a further validation of our world-class R&D and manufacturing capabilities that bring global healthcare standards to Indian patients at a lower cost. Through Intacept, we are able to reduce the cost of treatment for patients to about half of the imported Enbrel.”
Business Line
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…
Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…
New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…